Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SNCA | P37840 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186718 | 0.89 | SNCA (0.50) | CYP1A2TDP1ATMSNCAALDH1A1 | |
| SCHEMBL2989584 | 0.87 | CYP1A2 (0.69) | CYP1A2TDP1ATMSNCATSHR | |
| SCHEMBL2989578 | 0.87 | CYP1A2 (0.69) | CYP1A2TDP1ATMSNCATSHR | |
| SCHEMBL23200508 | 0.85 | ATM (0.51) | CYP1A2TDP1ATMSNCAALDH1A1 | |
| SCHEMBL10509624 | 0.85 | TDP1 (0.51) | CYP1A2TDP1ATMSNCACASP6 | |
| SCHEMBL3010413 | 0.85 | ATM (0.51) | CYP1A2TDP1ATMSNCAALDH1A1 | |
| SCHEMBL10509627 | 0.85 | TDP1 (0.51) | CYP1A2TDP1ATMSNCACASP6 | |
| SCHEMBL11630295 | 0.84 | NPC1 (0.56) | TDP1ATMSNCATSHRCASP6 | |
| SCHEMBL9651648 | 0.83 | MAOA (0.59) | TDP1ATMSNCAALDH1A1KMT2A | |
| SCHEMBL1028874 | 0.81 | PDGFRB (0.56) | CYP1A2TDP1ATMSNCAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447347-A | Preparation method for sunitinibmalate intermediate | PARLING SHANGHAI PHARMATECH CO LTD | 2015-03-25 | — | — | CN | claimed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| CN-116903471-B | Monofluoro/difluoro oxo allyl ester compound and preparation method thereof | 上海应用技术大学 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025077825-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIO-PULMONARY DISORDERS | FAUNA BIO INCORPORATED (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | METREA BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240246977-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE | BEONE MEDICINES I GMBH (CH) | 2024-07-25 | — | — | US | disclosed |
| CN-112638864-B | Traceless reductive cleavable linker molecules for peptide purification | 格瑞罗斯普罗泰恩科技公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2007104664-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
| US-7101886-B2 | Phenylalkyl and pyridylalkyl piperazine derivatives | WARNER LAMBERT COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1562919-A1 | PHENYLALKYL AND PYRIDYLALKYL PIPERAZINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1546145-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040186108-A1 | Phenylalkyl and pyridylalkyl piperazine derivatives | CHO STEPHEN SUNG YONG (US) | 2004-09-23 | — | — | US | disclosed |
| WO-2004041793-A1 | PHENYLALKYL AND PYRIDYLALKYL PIPERAZINE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004029048-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040067960-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | DAVIS JAMIE MARIE (US) | 2004-04-08 | — | — | US | disclosed |
| US-4160032-A | Oxindoles as sleep-inducers | SANDOZ, INC. (US) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186108-A1 | Phenylalkyl and pyridylalkyl piperazine derivatives | CNR1, CNR2, PMP22 | CYP1A2 29/4885TDP1 1289/4885ATM 3038/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | CYP1A2 1602/4885TDP1 3545/4885ATM 3660/4885 |
| US-20070213341-A1 | Spiroindolinone derivatives | MKI67, PKD1, RCC2 | CYP1A2 393/4885TDP1 3690/4885ATM 2027/4885 |
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | LPL, LIPA, PNLIP | CYP1A2 973/4885TDP1 301/4885ATM 796/4885 |
| US-20240246977-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE | BTK, CBL, SYK | CYP1A2 4471/4885TDP1 1237/4885ATM 1075/4885 |
| US-20040067960-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | HTR2C, CNR1, HTR2A | CYP1A2 87/4885TDP1 4139/4885ATM 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.